HAMN: High-Grade Appendiceal Mucinous Neoplasm Explained
HAMN, a high-grade appendiceal mucinous neoplasm, is a mucus-making tumor of the appendix that grows like a LAMN, pushing against the wall instead of invading it, but with high-grade, more abnormal cells. The 2025 consensus guidelines from the Peritoneal Surface Malignancy (PSM) Consortium treat HAMN on the same pathway as LAMN: removal of the appendix with clean margins when there is no spread, and cytoreductive surgery when mucin or tumor cells have spread through the abdomen. Follow-up is closer than for LAMN.
HAMN is one of the newest names in appendix pathology, and many doctors outside specialist centers see it rarely. People often come away from the first appointment unsure whether they have a precancer, a cancer, or something in between. I built this page to explain what HAMN is, how it differs from LAMN and adenocarcinoma, and what the 2025 guidelines recommend.
The treatment sections follow the 2025 consensus guidelines from the PSM Consortium. More than 130 specialists, including surgeons, medical oncologists, pathologists, and patient advocates, voted on each step, and Dr. Michael Foote, who reviewed this page, is one of the authors. Sources are listed at the bottom.
What HAMN is
HAMN stands for high-grade appendiceal mucinous neoplasm. Like a LAMN, it is a tumor of mucus-making cells that grows by pushing against the wall of the appendix rather than invading through it. The difference is in the cells themselves. In HAMN, the cells look high grade, meaning more abnormal under the microscope.
The term came out of the 2016 international pathology agreement led by the Peritoneal Surface Oncology Group International (PSOGI). Before then, tumors now called HAMN were often reported as noninvasive adenocarcinoma or cystadenocarcinoma. If an older report uses one of those words for a tumor without true invasion, it may be describing what is now called HAMN. Expert pathology review can sort this out, and the 2025 guidelines recommend it for every appendix tumor.
HAMN, LAMN, and adenocarcinoma
| Diagnosis | How it grows | How the cells look |
|---|---|---|
| LAMN | Pushes against the wall | Low grade |
| HAMN | Pushes against the wall | High grade |
| Mucinous adenocarcinoma | Invades into the surrounding tissue | Graded 1, 2, or 3 |
That growth pattern is why HAMN is not called adenocarcinoma. Under current World Health Organization rules, adenocarcinoma requires true infiltrative invasion. The appendiceal adenocarcinoma page covers that diagnosis.
How HAMN is found and the tests that follow
Like LAMN, HAMN is often found after an appendectomy for suspected appendicitis, or on a scan done for another reason. The 2025 guidelines recommend the same workup for both:
- A detailed history and physical exam.
- Blood tumor markers: CEA, CA-125, and CA 19-9, with CRP considered.
- CT or MRI of the abdomen and pelvis, if not already done.
- A colonoscopy to look for a separate growth in the colon.
- Review of the tissue by an expert pathologist and discussion at a multidisciplinary tumor board.
If HAMN is suspected from a scan, the next step is surgery by the least invasive safe approach, usually diagnostic laparoscopy, with biopsies of anything that looks like spread.
Treatment for HAMN under the 2025 guidelines
When there is no spread
The PSM Consortium recommends removing the appendix to a negative margin, meaning no tumor at the cut edge. This is the same approach as for LAMN. If tumor cells are at the margin, a repeat operation with the most conservative resection possible, such as a cuff resection, is recommended. Mucin or tumor cells only on the surface of the appendix still count as a negative margin, but call for regular surveillance.
This is one area where expert groups disagree. PSOGI supports considering a right hemicolectomy for HAMN even when there is no spread to the abdomen. The PSM Consortium favors resection to clean margins only. It is reasonable to ask your surgeon which approach they follow and why.
Chemotherapy
The 2025 guidelines say no evidence currently supports chemotherapy for HAMN that has not spread. They note that high-grade mucinous neoplasms should most likely be treated like low-grade ones in this respect.
When mucin or tumor cells have spread
- Acellular mucin limited to the area around the appendix (mucin with no tumor cells), fully removed: the guidelines say observation with surveillance can be considered.
- Acellular mucin spread further, or any mucin containing tumor cells: the guidelines recommend evaluation for cytoreductive surgery (CRS) with intraperitoneal chemotherapy, such as HIPEC.
- Grade 2 or grade 3 disease in the abdomen: chemotherapy through the vein is added to CRS. In that situation, the guidelines note the diagnosis would usually be considered adenocarcinoma with a background HAMN, because the main disease is invasive.
Spread from HAMN inside the abdomen is called pseudomyxoma peritonei (PMP). The Appendicure post on perforated HAMN covers what a perforation means when scans look clear.
Surveillance after HAMN
When surveillance is recommended, the 2025 guidelines describe a visit with a history and physical exam, CT or MRI of the abdomen and pelvis, and a CEA blood test plus any marker that was high at any point. The usual schedule for appendiceal mucinous neoplasms is every 6 to 12 months for 5 to 10 years, and the guidelines say higher-grade lesions call for more intense surveillance. For HAMN, that generally means staying toward the more frequent end of that range. Recurrence is most common in the first 3 years after surgery. Ask your team to put the exact schedule in writing.
The genetics of HAMN
A 2020 study sequenced 9 HAMNs alongside LAMNs and mucinous adenocarcinomas. Every HAMN carried a KRAS mutation, and 5 of the 9 carried a GNAS mutation, a pattern shared with LAMN. Four of the 9 HAMNs also had a TP53 or ATM mutation, changes not seen in any LAMN in the study. The authors suggested these extra changes may push HAMN toward more aggressive behavior. This was a very small study, so these numbers are early clues, not rules. Pooling genomic data from many people with HAMN is how researchers can test them, and it is why the Appendicure registry exists.
Add your HAMN data to the registry
The Appendicure Patient-Led Global Appendix Cancer Registry collects pathology, genomic, and molecular data from people with every appendiceal cancer type, including HAMN. It is IRB-reviewed, free, and open worldwide. Please use the form for where you live.
Already enrolled? Add new reports or correct your record.
Frequently asked questions about HAMN
What is HAMN?
HAMN is a high-grade appendiceal mucinous neoplasm: a mucus-making tumor of the appendix that pushes against the wall like a LAMN but has high-grade, more abnormal cells.
What is the difference between HAMN and LAMN?
Both grow by pushing against the appendix wall rather than invading it. LAMN has low-grade cells and HAMN has high-grade cells. The 2025 guidelines treat them on the same pathway, with closer follow-up for HAMN.
Is HAMN cancer?
HAMN is not called adenocarcinoma because it does not show true invasion. It can spread inside the abdomen as pseudomyxoma peritonei, so it needs proper treatment and follow-up.
Do I need a right hemicolectomy for HAMN?
The 2025 PSM Consortium guidelines favor removing the appendix to a clean margin only. The international PSOGI group supports considering a right hemicolectomy for HAMN even without spread.
Do I need chemotherapy for HAMN?
Not when it has not spread. The 2025 guidelines say no evidence supports chemotherapy for HAMN confined to the appendix. Chemotherapy is added if grade 2 or grade 3 disease is found in the abdomen.
How long is follow-up after HAMN?
The 2025 guidelines suggest imaging and a CEA blood test every 6 to 12 months for 5 to 10 years for appendiceal mucinous neoplasms, with more intense follow-up for higher-grade lesions such as HAMN.
Related reading
Sources
- Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvement. Cancer. 2025;131(13):e35867. doi.org/10.1002/cncr.35867
- Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement. Cancer. 2025;131(13):e35874. doi.org/10.1002/cncr.35874
- Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the PSOGI modified Delphi process. Am J Surg Pathol. 2016;40(1):14-26. doi.org/10.1097/PAS.0000000000000535
- Liao X, Vavinskaya V, Sun K, et al. Mutation profile of high-grade appendiceal mucinous neoplasm. Histopathology. 2020;76(3):461-469. doi.org/10.1111/his.13986
Medically reviewed by Michael Foote, MD, Medical Oncologist & Physician-Scientist, Memorial Sloan Kettering. This page was written with AI assistance. It is for education and does not replace advice from your own care team. Last updated November 2026.
